Kodiak’s DAYBREAK win clears both endpoints, with Zenkuda showing 24-week durability

Kodiak is a precommercial retinal biotech moving from late-stage development toward its first regulatory filing, with Zenkuda as the lead asset and tabirafusp-ted and KSI-101 expanding the pipeline. The DAYBREAK readout was expected in September 2026, so the timing itself was known; the new information is whether the drugs cleared the trial bar and whether Zenkuda showed a commercially meaningful dosing advantage.

Zenkuda cleared more than the minimum efficacy hurdle. The study was designed around non-inferiority to aflibercept on vision, and Zenkuda met that primary endpoint while matching or exceeding the comparator through loading. 〔0〕 The important incremental result is durability: 54% of patients reached a six-month interval under strict treat-to-dryness retreatment criteria, giving Kodiak a concrete differentiation claim rather than just another comparable anti-VEGF result. 〔1〕

Tabirafusp-ted validated the program but did not yet prove superiority. It met the vision primary endpoint and an anatomical key secondary endpoint, with p-values of 0.0036 and less than 0.0001 respectively. 〔2〕 That is a meaningful clinical win, but the filing frames the next test as ALTO in diabetic macular edema, where Kodiak is seeking superiority over aflibercept; DAYBREAK supports continued development more than it establishes a best-in-class bispecific profile.

The result advances Kodiak from clinical validation toward regulatory execution. The company now plans a multi-indication Zenkuda BLA in the fourth quarter of 2026 using five positive Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion. The filing does not establish approval, label breadth or launch economics, but it materially reduces the central development risk that had defined the company’s story.

Safety was supportive rather than the main surprise. Zenkuda reported no intraocular inflammation and a 0.5% cataract adverse-event rate versus 0.9% for aflibercept; tabirafusp-ted also showed low reported rates. 〔3〕 These data remove an obvious obstacle to the BLA narrative, but the core value of the release is the combination of non-inferior vision and extended dosing, not safety alone.

Bottom line: DAYBREAK turns Zenkuda from a promising durability thesis into a broad, BLA-ready clinical package, while keeping tabirafusp-ted alive as a potentially differentiated follow-on asset. It is meaningfully better than a simple endpoint pass because the durability result supplies the competitive story Kodiak needed.